Bard touts publication of Lutonix study in NEJM
C.R. Bard (NYSE:BCR) said last Thursday that a 2-year study of its Lutonix drug-coated balloon catheter was published in The New England Journal of Medicine. The 2-year Levant 2 study data showed non-inferiority of the device and a trend towards superiority, compared to standard percutaneous transluminal angioplasty, in the treatment of peripheral artery disease, the company said. “We want to thank the investigators involved in the Levant 2 trial for their authorship of this ground-breaking study. Publication of the study results in The New England Journal of Medicine demonstrates the hi...
Source: Mass Device - June 29, 2015 Category: Medical Equipment Authors: Fink Densford Tags: Catheters Clinical Trials Vascular C.R. Bard New England Journal of Medicine Source Type: news

Bard's Drug-Coated Angioplasty Balloon Continues to Show Efficacy
(Source: MDDI)
Source: MDDI - June 25, 2015 Category: Medical Equipment Authors: Arundhati Parmar Tags: Implantable Devices Source Type: news

Bard touts 2-year data on Lutonix
C.R. Bard (NYSE:BCR) said that data from a 2-year study of its Lutonix drug-coated balloon catheter showed positive results for the device when compared to standard percutaneous transluminal angioplasty. The 2-year Levant study data showed non-inferiority of the device and a trend towards superiority compared to standard PTA, the company said. Composite safety scores at 24 months were 78.7% for Lutonix, versus 70.9% for standard PTA. Primary patency, or the rate of lesion reoccurrence, was at 58.6% with Lutonix vs 53% with standard PTA, the study reports. The difference shows a 10.5% relative increase for the Lutonix devic...
Source: Mass Device - June 19, 2015 Category: Medical Equipment Authors: Fink Densford Tags: Cardiovascular Clinical Trials C.R. Bard Lutonix Inc. Source Type: news

MassDevice.com +3 | The top 3 medtech stories for June 12, 2015
Say hello to MassDevice +3, a bite-sized view of the top three medtech stories of the day. This feature of MassDevice.com’s coverage highlights our 3 biggest and most influential stories from the day’s news to make sure you’re up to date on the headlines that continue to shape the medical device industry.   3. Sorin, Cyberonics announce new slate for post-merger board Sorin Group and Cyberonics announced a new slate for the board of directors that will oversee the company after the expected close of their $1.4 billion merger in the 3rd quarter. Last month the companies announced the management roste...
Source: Mass Device - June 15, 2015 Category: Medical Equipment Authors: Melissa Annand Tags: News Well Source Type: news

Medtronic Initiates U.S. Launch of Fortrex™ PTA Balloon
Medtronic plc (NYSE: MDT) announced today the launch of the Fortrex™ over-the-wire (OTW) percutaneous transluminal angioplasty (PTA) balloon catheter. The Fortrex PTA balloon catheter utilizes a high pressure balloon to break up the blockages and open the vessels to help maintain arteriovenous (AV) access in the peripheral vascular system. (Source: News from Angioplasty.Org)
Source: News from Angioplasty.Org - June 14, 2015 Category: Cardiology Source Type: news

Medtronic launches Fortrex PTA balloon catheter in US
Medtronic (NYSE:MDT) said yesterday that it launched its Fortrex percutaneous transluminal angioplasty balloon catheter in the U.S. The Fortrex is designed to treat peripheral artery disease and maintain arteriovenous access for hemodialysis, the Fridley, Minn.-based company said. The catheter uses a balloon to break up plaque blockages in the peripheral vascular system, or blockages in hemodialysis patients at the dialysis sites, the company added. “Being able to maintain AV access for patients receiving hemodialysis for renal disease and kidney failure is critical as it is a patient’s lifeline. In the pa...
Source: Mass Device - June 11, 2015 Category: Medical Equipment Authors: Fink Densford Tags: Cardiovascular Catheters medtronic Source Type: news

MassDevice.com +3 | The top 3 medtech stories for June 10, 2015
Say hello to MassDevice +3, a bite-sized view of the top three medtech stories of the day. This feature of MassDevice.com’s coverage highlights our 3 biggest and most influential stories from the day’s news to make sure you’re up to date on the headlines that continue to shape the medical device industry.   3. Battelle pairs with Feinstein Institute to develop ‘neural tourniquet’ Battelle said that it’s partnering with the Feinstein Institute to develop a novel “neural tourniquet” designed to staunch blood loss using neurostimulation. The device functions by electricall...
Source: Mass Device - June 10, 2015 Category: Medical Equipment Authors: MassDevice Tags: News Well Plus 3 Source Type: news

Bard’s Lutonix DCB receives improved Medicare reimbursements
C.R. Bard (NYSE:BCR) said today that the U.S. Centers for Medicare and Medicaid Services has improved the payment for Bard’s Lutonix drug-coated balloon catheter through the Medicare hospital outpatient prospective payment system. The Murray Hill, N.J.-based company said that Medicare will now reimburse the full cost of its DCB device for percutaneous transluminal angioplasty, stenting, or atherectomy procedures. The new reimbursement determination is retroactive to April 1 this year, the company said. The Lutonix is the 1st FDA-approved DCB, Bard claims, and is used to treat patients with peripheral arterial disease...
Source: Mass Device - June 10, 2015 Category: Medical Equipment Authors: Fink Densford Tags: Cardiovascular Medicare C.R. Bard Centers for Medicare and Medicaid Services (CMS) Source Type: news

Medtronic Drug-Coated Balloon for Treatment of Peripheral Arterial Disease Shows Strong Results in Long Lesions
Presented for the first time today at EuroPCR during the "Hot line" session on "Peripheral interventions," new clinical data from two different studies show that the IN.PACT Admiral drug-coated balloon from Medtronic plc (NYSE: MDT) successfully treated long lesions in the superficial femoral and popliteal arteries. Prof. Dierk Scheinert, chairman of the division for interventional angiology at University-Hospital Leipzig in Germany, presented 12-month results for 157 patients enrolled in the IN.PACT Global Study's long lesion imaging cohort. (Source: News from Angioplasty.Org)
Source: News from Angioplasty.Org - June 3, 2015 Category: Cardiology Source Type: news

Contego Medical raises $6m for embolic filter tech
Contego Medical raises nearly $6 million in a Series B round it plans to use to expand its roster and develop its embolic protection balloon and stent-delivery systems. Contego Medical said it pulled in $5.6 million in a Series B round to advance its embolic protection technology for angioplasty balloon and stent-delivery catheters. Contego Medical, Hatteras Venture Partners, Lookout Capital, Medical Mutual, Mountain Group PartnersNews Well, Cardiovascular, Funding Roundup, Strokeread more (Source: Mass Device)
Source: Mass Device - April 27, 2015 Category: Medical Equipment Authors: Mark Hollmer Source Type: news

FDA approves blood pump system to help patients maintain stable heart function during certain high-risk cardiac procedures
The U.S. Food and Drug Administration today approved the Impella 2.5 System, a miniature blood pump system intended to help certain patients maintain stable heart function and circulation during certain high-risk percutaneous coronary intervention (HRPCI) procedures, such as balloon angioplasty and stenting, which re-open coronary arteries that are narrowed or blocked due to severe coronary artery disease (CAD). (Source: Food and Drug Administration)
Source: Food and Drug Administration - March 23, 2015 Category: American Health Source Type: news

Heart bypass surgery outperforms new generation stents
Despite the advent of a new generation of stents, patients with multiple narrowed arteries in the heart who received coronary artery bypass grafting fared better than those whose arteries were opened with balloon angioplasty and stents in a recent study. (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - March 16, 2015 Category: Science Source Type: news

Heart bypass surgery outperforms new generation stents
(American College of Cardiology) Despite the advent of a new generation of stents, patients with multiple narrowed arteries in the heart who received coronary artery bypass grafting fared better than those whose arteries were opened with balloon angioplasty and stents in a study presented at the American College of Cardiology's 64th Annual Scientific Session. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - March 16, 2015 Category: Global & Universal Source Type: news

Medicare Approves Transitional Pass-Through Payment for Outpatient Use of Medtronic Drug-Coated Balloon
The U.S. Centers for Medicare and Medicaid Services (CMS) has approved a transitional pass-through payment for Medtronic's IN.PACT Admiral drug-coated balloon (DCB) under the Medicare hospital outpatient prospective payment system (OPPS), removing a potential barrier to patient access to this new medical device, which represents a significant improvement to the standard of care for peripheral arterial disease in the upper leg. (Source: News from Angioplasty.Org)
Source: News from Angioplasty.Org - February 26, 2015 Category: Cardiology Source Type: news

CMS Approves Pass-Through Payment for Lutonix DCB for Outpatient Use
The U.S. Centers for Medicare and Medicaid Services (CMS) has approved a pass-through payment for C. R. Bard's Lutonix® drug-coated balloon (DCB) under the Medicare hospital outpatient prospective payment system. This approval follows a unanimous favorable recommendation from the FDA's Circulatory Systems Devices Advisory Panel, which voted 9 to 0 on each question of safety, efficacy and benefit/risk. (Source: News from Angioplasty.Org)
Source: News from Angioplasty.Org - February 26, 2015 Category: Cardiology Source Type: news

Medtronic Gains CE Mark for Euphora Semicompliant Coronary Balloon; Launches in Europe
Today Medtronic plc (NYSE: MDT) announced that its Euphora™ Semicompliant Balloon Dilatation Catheter has received the CE (Conformité Européene) mark and that the product has been launched, the first case being performed by Dr. Richard Edwards in the UK. While most think of stents when they think of interventional cardiology, balloons play an important role in percutaneous coronary interventions (PCI). (Source: News from Angioplasty.Org)
Source: News from Angioplasty.Org - February 17, 2015 Category: Cardiology Source Type: news

Boston Scientific to Distribute Bard's Lutonix Drug-Coated Balloon for Blockages in Leg Arteries
Boston Scientific (NYSE: BSX) and C. R. Bard, Inc. (NYSE: BCR) have announced that Bard's Lutonix® 035 drug-coated balloon will be distributed in the United States by Boston Scientific. The specific terms of the agreement were not disclosed. The Lutonix was the first drug-coated balloon (DCB) approved by the FDA for use in the superficial femoral or popliteal arteries in the leg. (Source: News from Angioplasty.Org)
Source: News from Angioplasty.Org - February 10, 2015 Category: Cardiology Source Type: news

Boston Scientific And C. R. Bard Announce Distribution Agreement For Lutonix® Drug Coated Balloon
Boston Scientific Corporation (NYSE: BSX) and C. R. Bard, Inc. (NYSE: BCR) ("Bard") today announced that Boston Scientific will distribute the Lutonix® 035 Drug Coated Balloon Percutaneous Transluminal Angioplasty Catheter (Lutonix DCB) in the United States under a limited distribution agreement reached with Bard. Terms of the agreement were not disclosed. (Source: Medical Design Online News)
Source: Medical Design Online News - February 10, 2015 Category: Medical Equipment Source Type: news

Medtronic Launches Drug-Coated Balloon for Peripheral Artery Disease in U.S.
Medtronic plc (NYSE: MDT) announced yesterday that its IN.PACT Admiral drug-coated balloon (DCB), approved last month by the FDA, is now available for use in the U.S. The first uses of this new addition to the interventional armamentarium were in New York, Michigan, Arizona, and Louisiana. The IN.PACT Admiral is the second such device approved by the FDA, the first being Bard's Lutonix back in October. (Source: News from Angioplasty.Org)
Source: News from Angioplasty.Org - February 6, 2015 Category: Cardiology Source Type: news

Spectranetics Completes Acquisition of Stellarex(TM) Drug Coated Balloon Assets From Covidien
COLORADO SPRINGS, Colo., Jan. 27, 2015 -- (Healthcare Sales & Marketing Network) -- The Spectranetics Corporation (SPNC) today announced it has completed the acquisition of Covidien's Stellarex(TM) drug coated balloon angioplasty (DCB) platform. The transa... Devices, Interventional, AcquisitionsSpectranetics, Covidien, Stellarex, drug coated balloon (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - January 27, 2015 Category: Pharmaceuticals Source Type: news

Consumer Information on: Medtronic IN.PACT Admiral Paclitaxel-coated PTA Balloon Catheter - P140010
The Medtronic IN.PACT Admiral Paclitaxel-coated Percutaneous Transluminal Angioplasty (PTA) Balloon Catheter (Medtronic DCB) uses a drug-coated balloon to re-open blocked or narrowed arteries in the thigh and knee due to peripheral artery disease (PAD). (Source: Food and Drug Adminstration (FDA): CDRHNew)
Source: Food and Drug Adminstration (FDA): CDRHNew - January 20, 2015 Category: Medical Equipment Source Type: news

Covidien's Stellarex Drug-Coated Angioplasty Balloon Receives CE Mark To Treat Peripheral Arterial Disease Patients
Covidien plc recently announced it has received CE Mark approval for its Stellarex drug-coated angioplasty balloon (DCB). (Source: Medical Design Online News)
Source: Medical Design Online News - January 12, 2015 Category: Medical Equipment Source Type: news

FDA Approves Medtronic Drug-Coated Balloon for Treating Peripheral Artery Disease in the Upper Leg
Medtronic, Inc. (NYSE: MDT) has announced that the FDA has approved its drug-coated balloon (DCB), the IN.PACT Admiral, for the treatment of peripheral artery disease (PAD) in the upper leg. The IN.PACT Admiral is the second such device approved by the FDA, the first being Bard's Lutonix back in October. The FDA approval of the IN.PACT was supported by a body of clinical evidence of 21 studies involving more than 3,500 patients worldwide, demonstrating the best clinical outcomes of any medical technology for the treatment of PAD in the SFA and popliteal arteries. (Source: News from Angioplasty.Org)
Source: News from Angioplasty.Org - January 7, 2015 Category: Cardiology Source Type: news

Medtronic Drug-Coated Balloon for Peripheral Artery Disease Tops Standard Balloon Angioplasty in Landmark Study
The results of a landmark study published this month in Circulation, the world's leading cardiovascular journal, indicate that a novel medical device from Medtronic, Inc. (NYSE: MDT) called the IN.PACT Admiral drug-coated balloon (DCB) significantly outperformed standard balloon angioplasty in the treatment of symptomatic peripheral artery disease in the upper leg -- specifically, the superficial femoral and proximal popliteal arteries. (Source: News from Angioplasty.Org)
Source: News from Angioplasty.Org - January 7, 2015 Category: Cardiology Source Type: news

Study: Medtronic's In.Pact Admiral balloon beats standard angioplasty
Medtronic touts a new study showing that its In.Pact Admiral drug-eluting balloon performed better than a standard angioplasty balloon in the treatment of symptomatic peripheral artery disease of the upper leg. Medtronic, American Heart Assn.News Well, Clinical Trials, Peripheral Artery Diseaseread more (Source: Mass Device)
Source: Mass Device - December 23, 2014 Category: Medical Equipment Authors: Val Kennedy Source Type: news

Covidien's Fortrex PTA Balloon Receives FDA 510(k) Clearance
Covidien plc recently announced U.S. Food and Drug Administration 510(k) clearance for its Fortrex over-the-wire (OTW) percutaneous transluminal angioplasty (PTA) balloon catheter. (Source: Medical Design Online News)
Source: Medical Design Online News - December 1, 2014 Category: Medical Equipment Source Type: news

Medtronic Acquisition of Covidien Receives U.S. FTC Clearance
Medtronic, Inc. (NYSE: MDT) and Covidien plc (NYSE: COV) today announced the receipt of U.S. Federal Trade Commission (FTC) clearance of Medtronic's proposed acquisition of Covidien. The FTC's clearance follows Medtronic's and Covidien's agreement to a proposed consent order, which includes a commitment to divest certain assets related to Covidien's drug-coated balloon catheter product. Medtronic's acquisition of Covidien is expected to close in early 2015 after receipt of certain additional regulatory clearances and approvals by both companies' shareholders and sanction by the High Court of Ireland. (Source: News from Angioplasty.Org)
Source: News from Angioplasty.Org - November 27, 2014 Category: Cardiology Source Type: news

Atherectomy and balloon angioplasty beat angioplasty alone in Covidien trial
Atherectomy and balloon angioplasty proves more effective than angioplasty alone in treating peripheral artery disease, according to new data from a Covidien study. CovidienNews Well, Clinical Trials, Peripheral Artery Diseaseread more (Source: Mass Device)
Source: Mass Device - November 6, 2014 Category: Medical Equipment Authors: Val Kennedy Source Type: news

5-Year Data for Zilver PTX Drug-Eluting Stent for Leg Arteries Show Continued Efficacy
Following up on the presentation of 4-year data for the Zilver PTX drug-eluting stent at last year's VIVA meeting, Cook Medical today announced the 5-year outcomes - and the results show that patients arteries have remained open, and that there has been no "late catch-up" with the Zilver. While patency was slightly lower at the 5-year mark than at 4-years for both the Zilver and standard balloon due to disease progression and other causes, the divergence between the two therapies actually grew from year 4 to 5, favoring the Zilver. (Source: News from Angioplasty.Org)
Source: News from Angioplasty.Org - November 5, 2014 Category: Cardiology Source Type: news

Medtronic's IN.PACT Drug-Coated Balloon Shows Safety and Efficacy for Peripheral Angioplasty in Diabetics
Data presented this morning at the VIVA 14 meeting in Las Vegas, Nevada, showed that patients treated with Medtronic's IN.PACT Admiral drug-coated balloon (DCB) for narrowings in their legs above-the-knee had significantly better outcomes than those treated with the standard "plain" balloon catheter, called percutaneous transluminal angioplasty (PTA). While these data were previously presented in April at the Charing Cross international symposium in London, today's session also showed that these positive findings for the DCB held true even for patients with diabetes, a population that typically presents with wors...
Source: News from Angioplasty.Org - November 5, 2014 Category: Cardiology Source Type: news

Medtronic's In.Pact Admiral balloon bests angioplasty in diabetics
Medtronic's In.Pact Admiral drug-eluting balloon bested angioplasty in treating diabetic peripheral artery disease patients, according to 1-year data from the In.Pact SFA trial. MedtronicNews Well, Clinical Trials, Peripheral Artery Diseaseread more (Source: Mass Device)
Source: Mass Device - November 4, 2014 Category: Medical Equipment Authors: Brad Perriello Source Type: news

Consumer Information on: Lutonix 035 Drug Coated Balloon PTA Catheter - P130024
The Lutonix 035 Drug Coated Balloon Percutaneous Transluminal Angioplasty Catheter (Lutonix DCB) uses a drug-coated balloon to re-open blocked or narrowed arteries in the thigh and knee due to peripheral artery disease (PAD). The balloon is coated on... (Source: Food and Drug Adminstration (FDA): CDRHNew)
Source: Food and Drug Adminstration (FDA): CDRHNew - October 29, 2014 Category: Medical Equipment Source Type: news

FDA Approves First Drug Eluting Angioplasty Balloon
The FDA has approved C.R. Bard’s Lutonix 035 Drug Coated Balloon (Lutonix DCB), a technology that may reduce restenosis of vessels treated by balloon angioplasty. This technology is the first of its kind to be approved for use in the femoral and popliteal arteries when they are stricken by Peripheral Artery Disease (PAD). (Source: Medical Design Online News)
Source: Medical Design Online News - October 16, 2014 Category: Medical Equipment Source Type: news

FDA Approves World's First Drug-Coated Angioplasty Balloon Catheter
(Source: MDDI)
Source: MDDI - October 14, 2014 Category: Medical Equipment Authors: Arundhati Parmar Tags: Implantable Devices Source Type: news

First Drug-Coated Balloon Approved by FDA for Leg Blockages (FREE)
By Larry Husten Edited by David G. Fairchild, MD, MPH, and Jaye Elizabeth Hefner, MD The FDA has approved the first drug-coated angioplasty balloon catheter to re-open blocked arteries in the superficial femoral and popliteal arteries. The … (Source: Physician's First Watch current issue)
Source: Physician's First Watch current issue - October 14, 2014 Category: Primary Care Source Type: news

FDA Approves Lutonix 035: First Drug-Coated Balloon for Blockages in Leg Arteries
The U.S. FDA has approved the first drug-coated balloon for use in opening up blockages in the peripheral arteries, specifically the superficial femoral or popliteal arteries in the leg. The Lutonix 035 was approved in Europe in 2012 but has taken an additional two years for the FDA to give it the go-ahead. An FDA panel unanimously recommended approval back in June, although there were questions regarding the results that showed no additional benefit in women above the therapy of a standard non-coated balloon. (Source: News from Angioplasty.Org)
Source: News from Angioplasty.Org - October 13, 2014 Category: Cardiology Source Type: news

First Drug-Coated Balloon Approved By FDA For Leg Blockages
The FDA today announced that it had approved  for use in the US the first drug-coated angioplasty balloon catheter to re-open blocked arteries in the thigh and knee (superficial femoral and popliteal arteries). The Lutonix 035 Drug Coated Balloon Percutaneous Transluminal Angioplasty Catheter (Lutonix DCB) is manufactured by CR Bard and has been available in Europe since 2012. (Source: Forbes.com Healthcare News)
Source: Forbes.com Healthcare News - October 10, 2014 Category: Pharmaceuticals Authors: Larry Husten Source Type: news

FDA approves first drug-coated angioplasty balloon catheter to treat vascular disease
The U.S. Food and Drug Administration today approved the Lutonix 035 Drug Coated Balloon Percutaneous Transluminal Angioplasty Catheter (Lutonix DCB). This is the first drug-coated balloon used to re-open arteries in the thigh (superficial femoral arteries) and knee (popliteal arteries) when narrowed or blocked as a result of peripheral artery disease (PAD). (Source: Food and Drug Administration)
Source: Food and Drug Administration - October 10, 2014 Category: American Health Source Type: news

TCT 2014: Medtronic's IN.PACT Admiral beats PTA in outcomes, costs
Medtronic unveils 1-year study results showing that its IN.PACT Admiral drug-coated balloon is clinically superior and more cost-effective than standard percutaneous transluminal angioplasty. Medtronic, TCT 2014News Well, Clinical Trials, Conference coverage, Minnesota, Peripheral Artery Disease, Transcatheter Cardiovascular Therapeutics symposium (TCT)read more (Source: Mass Device)
Source: Mass Device - September 16, 2014 Category: Medical Equipment Authors: Arezu Sarvestani Source Type: news

FDA OKs Medtronic's Euphora Non-Compliant Coronary Balloon Catheter
Coming just four months after its CE Mark European approval, the NC Euphora balloon has received the okay from the FDA for marketing in the United States. Non-compliant (NC) balloons are specifically designed to be used in post-stent dilatation, to ensure that the stent itself is fully expanded against the arterial wall. An under-expanded stent is associated with higher restenosis rates, as well as stent thrombosis, a phenomenon first described by Dr. Antonio Colombo in the early days of stenting. (Source: News from Angioplasty.Org)
Source: News from Angioplasty.Org - September 12, 2014 Category: Cardiology Source Type: news

Teleflex Receives FDA Clearance for 150 cm Length Arrow(R) GPSCath(R) Balloon Dilatation Catheters
PTA balloon catheters combine angioplasty with targeted injection system in a single device for use in below the knee procedures WAYNE, Pa.--(Healthcare Sales & Marketing Network)--Teleflex Incorporated (TFX), a leading global provider of medical device... Devices, Interventional, FDATeleflex, Arrow, GPSCath, Balloon Catheter, angioplasty (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - July 29, 2014 Category: Pharmaceuticals Source Type: news

Study Offers Reassurance About Newer Drug-Eluting Stents
Drug-eluting stents (DES) have been viewed as a great advance over earlier stents and balloon angioplasty because they result in many fewer cases of restenosis. But enthusiasm for the first generation of DES was somewhat curbed due to reports of late stent thrombosis (ST), a rare but very dangerous complication. Now findings from a large ongoing registry study provide some reassurance about the long-term safety of the new generation of drug-eluting stents in patients with heart attacks (STEMI). The results are published  in the Journal of the American College of Cardiology. (Source: Forbes.com Healthcare News)
Source: Forbes.com Healthcare News - July 1, 2014 Category: Pharmaceuticals Authors: Larry Husten Source Type: news

Peripheral Vascular Devices & Interventional Cardiology Market in...
ReportsnReports.com adds “North American Interventional Cardiology & Peripheral Vascular Devices Market by Angioplasty Balloon (Plain/Old, Cutting), Stent (Bioabsorbable, Drug-Eluting), Catheter...(PRWeb June 11, 2014)Read the full story at http://www.prweb.com/releases/North-america-industry/cardiology-peripheral/prweb11935323.htm (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - June 11, 2014 Category: Pharmaceuticals Source Type: news

Press Release: Medtronic Announces CE Mark and Launch of NC Euphora Coronary Balloon
Noncompliant Balloon Provides Superior Deliverability and Controlled Growth for Challenging Coronary Angioplasty Procedures. MedtronicNews Well, Regulatory/Clearance, Catheters, CE Mark, Minnesotaread more (Source: Mass Device)
Source: Mass Device - May 20, 2014 Category: Medical Equipment Authors: MassDevice Source Type: news

Medtronic Launches New Peripheral Angioplasty Catheter in Europe
Today Medtronic, Inc. (NYSE: MDT) announced the European launch of its latest product to address the problems of peripheral artery disease (PAD), the "TOTAL Across" crossing catheter, intended for use in the lower extremities, specifically those arterial blockages below the knee that often are the cause of critical limb ischemia. Today's announcement by Medtronic adds to their portfolio of peripheral devices, including the IN.PACT drug-eluting balloon, and several balloon catheters designed for use in challenging narrow below-the-knee blockages. (Source: News from Angioplasty.Org)
Source: News from Angioplasty.Org - February 13, 2014 Category: Cardiology Source Type: news

Medtronic Launches 'TOTAL Across' Crossing Catheter in Europe
New Peripheral Angioplasty Balloon Targets Challenging Lesions in Lower-Extremity, Including Below-the-Knee, Arteries Associated with Critical Limb Ischemia MINNEAPOLIS -- Feb. 13, 2014 --(Healthcare Sales & Marketing Network)-- Aligned with its commitm... Devices, Interventional, Product LaunchMedtronic, TOTAL across, crossing catheter, Angioplasty, Balloon catheter (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - February 13, 2014 Category: Pharmaceuticals Source Type: news

CCSVI surgery study
A randomised,double blind study of balloon angioplasty to treat CCSVI in people with MS found the procedure to be safe but "did not provide sustained improvement in MS patients. PR Web CCSVI - A to Z of MS (Source: Multiple Sclerosis Trust)
Source: Multiple Sclerosis Trust - November 22, 2013 Category: Neurology Source Type: news

Penile-Artery Angioplasty Gets Second Look for EDPenile-Artery Angioplasty Gets Second Look for ED
A small pilot trial is picking up where the ZEN trial of drug-eluting stents for ED left off, this time trying plain-old balloon angioplasty in the penile arteries. Heartwire (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - November 5, 2013 Category: Consumer Health News Tags: Cardiology News Source Type: news

Intact Vascular Announces Completion Of Enrollment Of The Tack Optimized Balloon Angioplasty (TOBA) Study
Intact Vascular, Inc., a developer of medical devices for minimally invasive peripheral vascular procedures, recently announced the completion of enrollment of the Tack Optimized Balloon Angioplasty (TOBA) study. (Source: Medical Design Online News)
Source: Medical Design Online News - October 4, 2013 Category: Medical Equipment Source Type: news

Heart attack death rates unchanged in spite of faster care at hospitals
Heart attack deaths have remained the same, even as hospital teams have gotten faster at treating heart attack patients with emergency angioplasty, according to a study in this week's New England Journal of Medicine. Hospitals across the country have successfully raced to reduce so-called door-to-balloon time, the time it takes patients arriving at hospitals suffering from a heart attack to be treated with angioplasty, to 90 minutes or less in the belief that it would save heart muscle and lives... (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - September 7, 2013 Category: Consumer Health News Tags: Cardiovascular / Cardiology Source Type: news